Retatrutide

What Is Retatrutide?

Retatrutide (development code LY3437943) is a synthetic peptide engineered by Eli Lilly and Company as a triagonist — a single molecule that simultaneously activates three distinct metabolic receptors: the Glucagon-Like Peptide-1 receptor (GLP-1R), the Glucose-dependent Insulinotropic Polypeptide receptor (GIPR), and the Glucagon receptor (GCGR).

This triple mechanism makes Retatrutide mechanistically distinct from earlier-generation GLP-1 agonists (semaglutide/Ozempic) and dual GLP-1/GIP agonists (tirzepatide/Mounjaro). By adding glucagon receptor agonism, Retatrutide introduces a third mechanism that directly increases energy expenditure through thermogenesis — not present in either semaglutide or tirzepatide.

In its pivotal Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving 12 mg weekly achieved a mean body weight reduction of 22.8% at 36 weeks, continuing to approximately 24% at 48 weeks — placing it ahead of all other approved or pipeline weight-loss medications by a substantial margin.

Mechanism of Action

GLP-1 Receptor Agonism

• Appetite suppression: GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and food intake significantly.
• Gastric emptying slowdown: Extends the sensation of satiety after meals, further reducing caloric intake.
• Insulin secretion enhancement: Stimulates glucose-dependent insulin secretion from pancreatic beta cells without causing hypoglycemia in normoglycemic individuals.

GIP Receptor Agonism

• Synergistic appetite reduction: GIP receptor activation in the CNS works synergistically with GLP-1 to enhance appetite suppression beyond what either achieves alone.
• Adipose tissue modulation: GIP receptors in fat tissue influence lipid metabolism and fat storage dynamics.

Glucagon Receptor Agonism — The Key Differentiator

• Increased energy expenditure: Glucagon receptor activation increases basal metabolic rate and thermogenesis — a mechanism not present in semaglutide or tirzepatide. This is believed to contribute meaningfully to Retatrutide's superior outcomes.
• Hepatic fat reduction: Glucagon agonism promotes hepatic fat oxidation, making Retatrutide of significant interest for NASH research.

Phase 2 Clinical Trial Results

Metabolic & Cardiometabolic Benefits

Beyond weight loss, Retatrutide demonstrated meaningful improvements in fasting glucose, insulin resistance (HOMA-IR), triglycerides, waist circumference, and blood pressure — consistent with weight-loss-associated cardiometabolic benefit.

NASH / Liver Fat Reduction

Given its glucagon receptor component, Retatrutide is actively being investigated for NAFLD and NASH. Early data suggests meaningful reductions in liver fat content, making it a candidate for dual metabolic-hepatic indications.

Reconstitution Protocol

Research-grade Retatrutide is supplied as a lyophilized powder. Reconstitute with Bacteriostatic Water (BAC water) for multi-dose use.

1. Wipe the rubber stoppers of both vials with alcohol swabs. Allow to air dry.
2. Draw the desired BAC water volume into a clean syringe (see table below).
3. Insert the needle at an angle and slowly inject BAC water along the inner vial wall. Never inject directly onto the powder.
4. Gently swirl until completely dissolved. Do not shake.
5. The solution should be clear and colorless. Discard if cloudy or discolored.
6. Label the vial with name, concentration, and date. Refrigerate immediately.

Reconstitution Reference Table

Vial Size	BAC Water	Concentration	2 mg Dose	4 mg Dose
5 mg	1 mL	5 mg/mL	0.40 mL (40 units)	0.80 mL (80 units)
10 mg	2 mL	5 mg/mL	0.40 mL (40 units)	0.80 mL (80 units)
20 mg	4 mL	5 mg/mL	0.40 mL (40 units)	0.80 mL (80 units)
30 mg	6 mL	5 mg/mL	0.40 mL (40 units)	0.80 mL (80 units)

Dosage & Titration Protocol

Retatrutide is administered once weekly via subcutaneous injection. Slow titration is essential to minimize gastrointestinal side effects.

Standard Titration Schedule (Based on Phase 2 Protocol)

Weeks	Weekly Dose	Notes
Weeks 1–4	0.5 mg	Starting dose; assess GI tolerance
Weeks 5–8	1 mg	Advance if tolerating well
Weeks 9–12	2 mg	Meaningful appetite suppression typically begins
Weeks 13–16	4 mg	Significant weight loss phase begins
Weeks 17–20	6 mg	Hold if GI side effects increase
Weeks 21–24	8 mg	Upper range for most research protocols
Weeks 25+	8–12 mg	Maintenance; individualized to tolerance

Side Effects & Safety Considerations

Side Effect	Incidence (12 mg)	Management
Nausea	~45–55%	Slow titration; smaller meals; antiemetics if needed
Vomiting	~20%	Usually resolves; hold dose escalation if persistent
Diarrhea	~20%	Typically transient; hydration
Constipation	~15%	Hydration; dietary fiber
Heart rate increase	~5–10 bpm	Glucagon-mediated; monitor in cardiac history
Injection site reactions	Mild, common	Rotate injection sites weekly

Muscle Mass Preservation

Like all effective weight-loss agents, Retatrutide can cause loss of lean mass alongside fat. Adequate protein intake (1.6–2.2 g/kg bodyweight) and resistance training are strongly recommended throughout the protocol to preserve muscle tissue.

Storage Guidelines

State	Temperature	Duration	Notes
Lyophilized powder	Refrigerator (2–8°C)	Up to 24 months	Protect from light; keep sealed
Reconstituted solution	Refrigerator (2–8°C)	Up to 28 days	Do not freeze; discard if cloudy
In-use vial	Room temp or refrigerator	Up to 14 days at room temp	Keep below 30°C if at room temp

Primary Research Sources

• Jastreboff, A.M. et al. (2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 389, 514–526.
• Nauck, M.A. & D'Alessio, D.A. (2022). "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes." Cell Metabolism.
• Samms, R.J. et al. (2021). "Selective GIP Receptor Agonism Improves Metabolic Parameters." Cell Metabolism.
• Finan, B. et al. (2015). "Unimolecular Dual Incretins Maximize Metabolic Benefits." Science Translational Medicine.